Adherex Technologies (FENC) Projected to Release Quarterly Earnings on Thursday

Adherex Technologies (NASDAQ:FENC) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Adherex Technologies to post earnings of $0.0960 per share and revenue of $18.87 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Adherex Technologies (NASDAQ:FENC) last posted its earnings results on Thursday, August 13th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. Adherex Technologies had a negative return on equity of 5.71% and a negative net margin of 6.09%. The business had revenue of $17.87 million during the quarter, compared to the consensus estimate of $16.21 million. On average, analysts expect Adherex Technologies to post $0.28 EPS for the current fiscal year and $0.97 EPS for the next fiscal year.

Adherex Technologies Stock Performance

Shares of NASDAQ:FENC opened at $10.83 on Tuesday. Adherex Technologies has a 52 week low of $5.65 and a 52 week high of $13.25. The company’s fifty day moving average is $10.75 and its 200-day moving average is $9.30.

Wall Street Analyst Weigh In

Several brokerages have recently commented on FENC. B. Riley Financial reissued a “buy” rating and issued a $18.00 target price (up from $16.00) on shares of Adherex Technologies in a report on Wednesday, August 12th. Wedbush boosted their target price on Adherex Technologies from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Adherex Technologies in a research note on Wednesday, September 9th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Insider Activity at Adherex Technologies

In other Adherex Technologies news, CFO Robert Andrade sold 75,000 shares of Adherex Technologies stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer owned 217,675 shares of the company’s stock, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider directly owned 9,519 shares in the company, valued at approximately $115,941.42. The trade was a 55.76% decrease in their position. The disclosure for this sale is available in the SEC filing. 10.73% of the stock is currently owned by insiders.

Adherex Technologies Company Profile

Fennec Pharmaceuticals, Inc, formerly known as Adherex Technologies, is a biopharmaceutical company focused on developing and commercializing therapies for pediatric cancer. The company’s lead product is PEDMARK (sodium thiosulfate), a platinum-based chemotherapy protective agent intended to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children with localized, non-metastatic solid tumors.

PEDMARK received approval from the U.S. Food and Drug Administration in 2022.